Advertisement
Research Article| Volume 17, ISSUE 2, P280-289, March 1995

Chemotherapy administered using two-route infusion of cisplatin and sodium thiosulfate and intravenous infusion of vinblastine and peplomycin in patients with oral cancer

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The therapeutic effects of neo-adjuvant chemotherapy administered by two-route infusion of cisplatin and its antidote, sodium thiosulfate, and intravenous infusion of vinblastine and peplomycin were studied in 22 patients with previously untreated squamous cell carcinoma of the oral cavity or maxillary sinus. The overall response rate to chemotherapy was 90.9%, with a complete response in 12 patients (54.5%), a partial response in 8 patients (36.4%), and no change in 12 patients (9.1%). Histologic assessment showed a grade V response in 7 patients (31.8%), grade IV in 3 patients (13.6%), grade III in 5 patients (22.7%), grade II in 4 patients (18.2%), and grade I in 3 patients (13.6%). The cumulative 5-year survival rate, including 3 patients who died of another disease, was 72.2%. Leukocytopenia, an important side effect apparently induced by vinblastine, was seen, but no life-threatening complications occurred. Renal toxicity by cisplatin was minimal because of the use of sodium thiosulfate and fosfomycin. These data indicate that this mode of chemotherapy may be more effective for treating head and neck cancer than ordinary chemotherapy, from clinical and histologic stand-points. The high complete-response rate is especially noteworthy. No serious side effects or reductions in treatment period occurred. The results are preliminary and additional studies using a larger patient population are needed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wittes RE
        • Cvitkovic E
        • Shar J
        • et al.
        Cis-diaminoedichloroplatinum (II) (PPD) in the treatment of epidermoid carcinoma of the head and neck.
        Cancer Treat Rep. 1977; 61: 359-366
        • Brown AW
        • Blom J
        • Butler WM
        • et al.
        Combination chemotherapy with vinblastine, bleomycin, and cis-diaminedichloroplatinum (II) in squamous cell carcinoma of the head and neck.
        Cancer. 1980; 45: 2830-2835
        • Ervin TJ
        • Weichselbaum R
        • Miller D
        • et al.
        Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).
        Cancer Treat Rep. 1981; 65: 787-791
        • Kish JA
        • Weaver A
        • Jacobs J
        • et al.
        Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
        Cancer. 1984; 53: 1819-1824
        • Spaulding MB
        • Klotch D
        • Grillo J
        • et al.
        Adjuvant chemotherapy in the treatment of advanced tumors of the head and neck.
        Am J Surg. 1980; 140: 538-541
        • Uozumi J
        • Sagiyama K
        • Taniguchi S
        • et al.
        “Two route infusion chemotherapy” using cis-diaminedichloroplatinum (II) and its antidote, sodium thiosulfate, for metastatic liver tumors in rats.
        Jpn J Surg. 1982; 12: 456-462
        • Uozumi J
        • Sagiyama K
        • Aoki K
        • et al.
        Effectiveness of “two-route chemotherapy” using cisplatin and its antidote, sodium thiosulfate, on life span of rats bearing metastatic liver tumors.
        Cancer Treat Rep. 1983; 67: 1067-1074
        • Sagiyama K
        • Uozumi J
        • Aoki K
        • et al.
        Efficiency of “two route chemotherapy” using intra-arterial cisplatin and IV sodium thiosulfate, its antidote, in rat bladder tumor.
        Cancer Treat Rep. 1983; 67: 567-572
        • Shimosato Y
        Histological studies on irradiated lung tumors.
        Gann. 1964; 55: 521-535
      1. a
        • Ishizawa M
        • Taniguchi S
        • Baba T
        Protection by sodium thiosulfate and thiourea against lethal toxicity of cis-diaminedichloroplatinum (II) in bacteria and mice.
        Jpn J Pharmacol. 1981; 31: 883
      2. b
        • Ishizawa M
        • Taniguchi S
        • Baba T
        Protection by sodium thiosulfate and thiourea against lethal toxicity of cis-diaminedichloroplatinum (II) in bacteria and mice.
        Jpn J Pharmacol. 1981; 31: 889
        • Taniguchi S
        • Baba T
        “Two route chemotherapy” using cis-diaminedichloroplatinum (II) and its antidote, sodium thiosulfate, for peritoneally disseminated cancer in rats.
        Gann. 1982; 73: 475-479
        • Bruce WR
        • Meeker BE
        • Valeriote FA
        Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo.
        J Natl Cancer Inst. 1966; 37: 233-245
        • Clark JR
        • Fallon BG
        • Dreyfuss AI
        • et al.
        Chemotherapeutic strategies in the multi-disciplinary treatment of the head and neck cancer.
        Semin Oncol. 1988; 15: 35-44
        • Busse PM
        • Clark JR
        • Beard CJ
        • et al.
        Primary site management following induction chemotherapy with cis-platinum, 5-fluorouracil, and leucovorin.
        Head Neck. 1993; 15: 413-418
        • Howell SB
        • Taetle R
        Effect of sodium thiosulfate on cis-dichlorodiamminoplatinum (II) toxicity and antitumor activity in L 1210 leukemia.
        Cancer Treat Rep. 1980; 64: 611-616
        • Bertelli A
        • Giovannini L
        • Paparelli A
        Reduced gentamycin nephrotoxicity by fosfomycin association.
        Future Trends Chemother. 1981; 4: 429-432
        • Neuman M
        Comparative study of the renal toxicity of amikacin alone and in combination with fosfomycin.
        Int J Clin Pharmacol Res. 1982; 11: 9-20
        • Inoue S
        • Niizato T
        • Takeda U
        • et al.
        Protective effects of fosfomycin on the experimental nephrotoxicity induced by dibekacin.
        J Pharmacobio-Dyn. 1982; 5: 659-669
        • Schweitzer VG
        • Dolan DF
        • Davidson T
        • et al.
        Amelioration of cisplatin-induced cytotoxicity by fosfomycin.
        Laryngoscope. 1986; 96: 948-958
        • Inoue S
        • Niizato T
        • Komiya I
        • et al.
        Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats.
        J Pharm Dyn. 1982; 5: 941-950
        • Kawashima T
        • Wada T
        • Morita N
        Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin.
        Jpn J Cancer Chemother. 1993; 20 (In Japanese): 2043-2048